Success Metrics

Clinical Success Rate
84.0%

Based on 21 completed trials

Completion Rate
84%(21/25)
Active Trials
0(0%)
Results Posted
67%(14 trials)
Terminated
4(10%)

Phase Distribution

Ph phase_3
2
5%
Ph phase_4
2
5%
Ph not_applicable
5
13%
Ph phase_2
15
38%
Ph phase_1
4
10%

Phase Distribution

4

Early Stage

15

Mid Stage

4

Late Stage

Phase Distribution28 total trials
Phase 1Safety & dosage
4(14.3%)
Phase 2Efficacy & side effects
15(53.6%)
Phase 3Large-scale testing
2(7.1%)
Phase 4Post-market surveillance
2(7.1%)
N/ANon-phased studies
5(17.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.8%

21 of 26 finished

Non-Completion Rate

19.2%

5 ended early

Currently Active

0

trials recruiting

Total Trials

40

all time

Status Distribution
Completed(21)
Terminated(5)
Other(14)

Detailed Status

Completed21
unknown14
Terminated4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
40
Active
0
Success Rate
84.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (14.3%)
Phase 215 (53.6%)
Phase 32 (7.1%)
Phase 42 (7.1%)
N/A5 (17.9%)

Trials by Status

unknown1435%
withdrawn13%
terminated410%
completed2153%

Recent Activity

Clinical Trials (40)

Showing 20 of 40 trialsScroll for more
NCT02512718Phase 1

Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation

Completed
NCT00910104Phase 2

Cholestasis Reversal: Efficacy of IV Fish Oil

Completed
NCT02534077

Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants

Unknown
NCT02328768

Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children

Unknown
NCT00826020Phase 2

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

Completed
NCT02486042Phase 2

Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

Completed
NCT01845116Phase 2

Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury

Completed
NCT04647604Phase 2

Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -

Completed
NCT04697888Phase 2

Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease

Completed
NCT00738101Not Applicable

Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants

Completed
NCT03561194

Omegaven Protocol:Intermediate Size Patient Population

Unknown
NCT01601652Phase 1

Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis

Completed
NCT02148146

Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis

Unknown
NCT00862446Phase 4

Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease

Completed
NCT00512629Phase 1

Cholestasis Prevention: Efficacy of IV Fish Oil

Completed
NCT04467138

High Dose Intravenous Fish Oil Reduces Inflammation

Completed
NCT03662282Phase 3

Omegaven as Alternative Parenteral Fat Nutrition

Completed
NCT01173159Not Applicable

Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis

Completed
NCT00969332Phase 2

A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease

Terminated
NCT02370251Phase 2

Compassionate Use of Omegaven in Children

Completed

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
40